Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited is an early-stage bioscience company that commenced operations in Hong Kong in 2014. The company focuses on the research, development and commercialization of traditional Chinese medicine for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting the immune system. Regencell has completed its first research study using personalized TCM formula for ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe patients initially in Hong Kong and subsequently in other markets.